Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin With or Without CPI-613 in Advanced Biliary Tract Cancer
NCT04203160Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in biliary tract cancer (BTC), sponsored by University of Michigan Rogel Cancer Center. Started Jun 2020; status: terminated.
02
Drugs
devimistat
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04203160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203160.